Madison Explorations, Inc.
OTCQB : MDEX

September 26, 2014 07:30 ET

Madison Explorations, Inc.'s New CEO Announces a Corporate Update to the Shareholders

SALT LAKE CITY, UTAH--(Marketwired - Sept. 26, 2014) - Madison Explorations, Inc., (OTCQB:MDEX) (the "Company") a leader in smokeless cannabinoid delivery technology, announces that it's new CEO, Mr. Brent Inzer, today has issued a corporate update to the MDEX shareholders.

As CEO of Madison Explorations, Inc. I would like to take this opportunity to update our shareholders on the current status of our Company and outline both our short and long term goals for the Company.

MDEX is uniquely positioned to become the leading smokeless cannabinoid technology provider, establishing a strong reputation for the highest quality, dosage reliability and formulation innovation. The Company is continuing its development and improvement of the products, production methods and formulations for its proprietary technology "CannaStrips" and is in advanced development of a number of additional smokeless delivery systems designed specifically for smokeless cannabinoid therapy.

Our immediate goal is to implement the Company's business development strategy. The Company intends to license the CannaStrips technology, which will include proprietary equipment being leased to CannaStrip's licensees that have State approved marijuana production facilities and/or dispensaries. We intend to focus initially on California, Colorado and Washington State. The Company has begun discussions with several licensed marijuana facilities and has received strong interest for our smokeless technology CannaStrips.

The Company is continuing to expand upon the proven smokeless delivery system CannaStrips with a series of additional smokeless delivery technologies. We are very excited about some of the initial beta tests of these technologies. The Company will continue to deliver cannabinoids variations for the clinical treatment of sleep disorders, seizures, cancer symptoms and pain therapy. With the advent of recreational use, the need for precise dosage and accurate categorizing of cannabis strains and possible effects is essential for responsible use of cannabis products. The Company has begun formulations for recreational users with these expectations in mind and all products produced with our technologies will be tested both in our lab and independently verified by outside laboratories for THC concentrations, cannabinoid consistency and acute dosage.

The Company is in the process of creating an advisory board consisting of medical professionals that CannaStrips has relied on in connection with its development of low THC high CBD cannabinoid strips designed for the treatment of severe forms of childhood epilepsy and therapies for a number of cancer related symptoms. Brent Inzer commented "The Company has had a long standing commitment to identifying and pursuing the benefits of cannabinoid treatments for these patients. This commitment has been and will be a priority of the CannaStrips team and we intend to continue to contribute the Company's experience and resources to the benefit of those patients".

Over the last five years, the Medical Marijuana industry has experienced a surge in industry revenue as a result of favorable legislation toward growing and distributing cannabis for medical purposes. With an estimated market value approaching the 1.5 billion dollar figure, we intend to play a major role in legitimizing this market and delivering a trusted product with our smokeless technologies.

Brent Inzer

CEO, Madison Explorations, Inc.

Forward Looking Statements

This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as "expects", "intends", "estimates", "projects", "anticipates", "believes", "could", and other similar words. All statements addressing product performance, events, or developments that Madison Explorations, Inc. expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in Madison Explorations, Inc.'s Quarterly and Annual Reports filed with the United States Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should any of Madison Explorations, Inc.'s underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Madison Explorations, Inc.'s forward-looking statements. Except as required by law, Madison Explorations, Inc. disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that Madison Explorations, Inc. files from time to time with the SEC, including its Annual, Quarterly and Current Reports.

For further information about Madison Explorations, Inc. please visit the company's website at http://cannabinoidstrips.com

Contact Information